Characterization of sleep apnea among a sample of adults from Samoa

Supplementary Material

Lacey W. Heinsberg, PhD, RN*; Alysa Pomer, PhD; Brian E. Cade, PhD; Jenna C. Carlson, PhD; Take Naseri, MBBS, MPH; Muagututia Sefuiva Reupena, MS; Satupa'itea Viali, MBChB, MPH; Daniel E. Weeks, PhD; Stephen T. McGarvey, PhD, MPH; Susan Redline, MD; Nicola L. Hawley, PhD

*Corresponding author Department of Human Genetics School of Public Health University of Pittsburgh E-mail: law145@pitt.edu

TABLE OF CONTENT		
Table/Figure/Section	Title	Page
Abstract	Translated Abstract (Samoan)	2 3
Methods S1	Expanded methods: WatchPAT data cleaning and quality control	3
Code S1	R code used to adjust for non-representational sampling and sample enrichment for the <i>CREBRF</i> obesity-risk allele.	4
Table S1	Comparison of sample characteristics between overall sample and subset with WatchPAT data.	6
Table S2	Sleep apnea categories by AHI 3%, AHI 4%, and ODI 4% across supine/non-supine positions and REM and non-REM sleep cycles.	7
Table S3	Comparison of observed sample sleep apnea category frequencies and <i>CREBRF</i> -adjusted prevalence estimates.	8
Table S4	Percent time spent <90% oxygen saturation, broken down by sleep apnea category.	9
Figure S1	Sina with violin plots of sleep apnea measures by categorical participant characteristics.	10
Figure S2	Sina with violin plots of sleep apnea measures by additional sleep environmental factors.	12
Figure S3	Rain cloud plots describing sleep apnea measures more detailed age group and sex.	13
Figure S4	Scatterplots of sleep apnea measures by continuous level participant characteristics.	14
Table S5	Results of linear regression examining associations of square root transformed sleep apnea measures with <i>CRBERF</i> genotype while controlling for age and sex (Table S3a), <i>CREBRF</i> genotype while controlling for age, sex, and BMI (Table S3b), and <i>CREBRF</i> genotype while controlling for age, sex, and T2DM (Table S3c).	15
Figure S5	Mosaic plot depicting the proportional distribution of sleep apnea categories by categorical BMI and sex.	16
Figure S6	Mosaic plot depicting the proportional distribution of sleep apnea categories by categorical BMI and categorical age.	17
Figure S7	Mosaic plot depicting the proportional distribution of sleep apnea categories by categorical age and sex.	18
Figure S8	Mosaic plot depicting the proportional distribution of sleep apnea categories by <i>CREBRF</i> rs373863828 genotype and sex.	19

Translated Abstract

A practice of our research group is to make an abstract that has been translated to Samoan available. At this time, only English language text is allowed by medRxiv. A Samoan translation is available upon request from <u>law145@pitt.edu</u>.

Methods S1. WatchPAT data cleaning and quality control: Data collection was attempted in 391 participants. Data were loaded from the WatchPAT device to a secure project computer and transferred to Brigham and Women's Hospital in Boston, USA via secure file transfer daily. Studies were initially scored using the device's automated zzzPAT software, editing events and sleep stages using an approach described by Zhang et al.¹ The algorithm was initially used to detect events associated with 4% desaturation criteria and then manually annotated such that events in non-REM sleep that were not accompanied by both a reciprocal decrease in the peripheral arterial tonometry signal and increase in heart rate were deleted. The AHI 3% was then calculated by retaining events that were identified to have a greater than or equal to 3% desaturation and less than a 4% desaturation and accompanied by both reciprocal peripheral arterial tonometry and heart rate changes. Any event that occurred during a position change was deleted. Sleep stages were automatically analyzed and edited if they did not show stage-specific patterns of heart rate, oxygen saturation, and peripheral arterial amplitude. Studies required a minimal of 3.7 hours of data on the oximetry and peripheral artery tonometry channels to be included. Post-QC, 330 participants were included for analyses.

```
Code S1. R code used to adjust for non-representational sampling and sample enrichment for the CREBRF obesity-risk allele.
# (1) Calculate expected genotype frequencies in the general population
# assuming a MAF p = 0.259
p <- 0.259
q <- 1 - p
freq_GG <- q^2</pre>
freq_AG <- 2 * p * q
freq_AA <- p^2</pre>
freq_GG
## [1] 0.549081
freq AG
## [1] 0.383838
freq AA
## [1] 0.067081
# (2) Calculate observed genotype frequencies in the sample
# 2a. Calculate the total number of participants of each genotype
total_GG <- sum(df$genotype_code == "GG")</pre>
total_AG <- sum(df$genotype_code == "AG")</pre>
total AA <- sum(df$genotype code == "AA")</pre>
total GG
## [1] 145
total_AG
## [1] 139
total AA
## [1] 46
# 2b. Calculate the frequency by dividing genotype-specific counts by total
# participant count (n=330)
freq_GG_observed <- total_GG/dim(df)[1]</pre>
freq_AG_observed <- total_AG/dim(df)[1]</pre>
freq_AA_observed <- total_AA/dim(df)[1]</pre>
freq_GG_observed
## [1] 0.4393939
freq_AG_observed
## [1] 0.4212121
freq AA observed
## [1] 0.1393939
# (3) Calculate weights for each genotype in our sample by dividing the
# expected (population) genotype frequency with the observed (sample) genotype
# frequency 3a. Calculate weights
weight_GG <- freq_GG/freq_GG_observed</pre>
weight_AG <- freq_AG/freq_AG_observed</pre>
weight AA <- freq AA/freq AA observed
```

weight_GG

SAMOA WATCHPAT ## [1] 1.249633 weight_AG ## [1] 0.9112701 weight_AA ## [1] 0.4812333 # 3b. Add the weight variable to data frame df <- df %>% mutate(weight = case_when(genotype_code == "GG" ~ weight_GG, genotype_code == "AG" ~ weight_AG, genotype_code == "AA" ~ weight_AA)) # (4) Adjust counts of the categorical AHI variable (cahi_3p) based on the step 3 weights counts <- df %>% group by(cahi 3p) %>% summarise(weighted_count = sum(weight), raw_count = n()) %>% ungroup counts ## # A tibble: 4 × 2 ## cahi_3p weighted_count raw_count ## <fct> <dbl> <int> ## 1 None 40.3 40 ## 2 Mild 112. 109

3 Moderate

4 Severe

116.

61.7

114

67

Table S1. Comparison of sample characteristics between overall sample and subset with WatchPAT data.

Characteristic	Overall $(n - 510)$	Subset $(n - 330)$	p-value ⁴
Characteristic	(n = 519)	(n = 330)	0.776
Age (years) ¹	52.2 (10.0)	52.0 (9.9)	0.776
Sex ²	222(44.0)	154(467)	0 (12
Male	233 (44.9)	154 (46.7)	0.613
<i>Female</i>	286 (55.1)	176 (53.3)	0.570
BMI $(kg/m^2)^1$	35.8 (7.7)	35.5 (7.5)	0.579
Missing	16	1	0.000
Abdominal-hip ratio ¹	0.98 (0.07)	0.98 (0.07)	0.999
Missing	16	2	
Type 2 Diabetes ²	(1 (10 1))	40 (10 0)	0.000
None	61 (12.1)	40 (12.2)	0.999
Pre-diabetes	259 (51.5)	169 (51.5)	
Diabetes	183 (36.4)	119 (36.3)	
Missing	16	2	
Hypertension ²	224 (64.0)	015 (66.5)	0.720
No	324 (64.9)	215 (66.6)	0.630
Yes	175 (35.1)	108 (33.4)	
Missing	20	7	
Asthma ²			
No	494 (95.6)	316 (95.8)	0.886
Yes	23 (4.4)	14 (4.2)	
Missing	2	0	
CREBRF rs373863828 genotype ²			
GG	224 (43.2)	145 (43.9)	0.254
AG	201 (38.7)	139 (42.1)	
AA	94 (18.1)	46 (13.9)	
Census Region ²			
AUA	116 (22.4)	68 (20.6)	0.753
NWU	221 (42.6)	139 (42.1)	
ROU	182 (35.0)	123 (37.3)	
Education (years) ¹	11.2 (2.7)	11.3 (2.9)	0.610
Missing	1	0	
Relationship Status ²			
Not partnered	95 (18.3)	57 (17.3)	0.693
Partnered	423 (81.7)	273 (82.7)	
Missing	1	0	
Alcohol ²			
No	478 (92.1)	305 (92.4)	0.864
Yes	41 (7.9)	25 (7.6)	
Smoking ²			
No	320 (61.8)	207 (62.9)	0.738
Yes	198 (38.2)	122 (37.1)	
Missing	1	1	
Material Lifestyle Score (no. household			
assets) ¹	8.0 (4.0)	8.0 (4.1)	0.999
Missing	3	2	
Accelerometer-measured physical activity			
(minutes/day) ³	73.0 (82.7)	75.3 (88.6)	0.497
Missing	87	39	

¹mean (SD); ²n (%); ³median (IQR); ⁴Statistical testing: T-test (variables with superscript ¹), chi-square test (variables with superscript ²), or Mann-Whitney U Test (variables with superscript ³); AUA = Apia Urban Area; NWU = Northwest 'Upolu; ROU = Rest of 'Upolu; Hypertension, defined as an average value \geq 140/90 mmHg and/or current hypertension medication use; Diabetes, based on Hemoglobin A1c values or current use of diabetes medication; Asthma, self-report history of asthma diagnosis; Smoking, defined based on self-report of current use of cigarettes, cigars, or pipes; Alcohol, defined based on self-report of consumption of alcohol in the past 12 months; Moderate-vigorous physical activity, average minutes/day measured using accelerometer.

	All (n=316) Male (n=152)					Female (n=164)			
Supine	AHI 3%	All (n=316) AHI 4%	ODI 4%	AHI 3%	AHI 4%	ODI 4%	AHI 3%	AHI 4%	ODI 4%
All categories	AIII 3 /0	AIII 4 /0	ODI 4 /0	AIII J /0	AIII 4 /0	ODI 470	AIII 570	AIII 4 /0	ODI 4 /0
None/minimal sleep apnea (<5 events/hr)	33 (10.4)	96 (30.4)	87 (27.5)	10 (6.6)	37 (24.3)	33 (21.7)	23 (14.0)	59 (36.0)	54 (32.9)
Mild (5 to <15 events/hr)	64 (20.3)	89 (28.2)	91 (28.8)	25 (16.4)	38 (25.0)	40 (26.3)	39 (23.8)	51 (31.1)	51 (31.1)
Mild (5 to <15 events/hr) Moderate (15 to<30 events/hr)	92 (29.1)	75 (23.7)	82 (25.9)	36 (26.7)	36 (23.7)	38 (25.0)	56 (34.1)	39 (23.8)	44 (26.8)
Severe (\geq 30)	127 (40.2)	56 (17.7)	56 (17.7)	81 (53.3)	41 (27.0)	41 (27.0)	46 (27.9)	15 (9.1)	15 (9.1)
Clinical categories	127 (40.2)	50(17.7)	50(17.7)	01 (33.3)	41 (27.0)	41 (27.0)	40 (27.7)	15 (9.1)	15 (9.1)
Potentially actionable (≥ 5 events/hr)	283 (89.6)	220 (69.6)	229 (72.4)	142 (96.4)	115 (75.7)	119 (78.3)	141 (85.8)	105 (64.0)	110 (67.0)
Clinically actionable (≥ 15 events/hr)	219 (69.3)	131 (41.4)	138 (43.6)	112 (90.1)	77 (50.7)	79 (52.0)	102 (62.0)	54 (32.9)	59 (35.9)
	217 (07.5)	All (n=315)	150 (45.0)		Male (n=148)			Female (n=16	
Non-supine	AHI 3%	All (11–315) AHI 4%	ODI 4%	AHI 3%	AHI 4%	ODI 4%	AHI 3%	AHI 4%	ODI 4%
All categories	AIII 3 /0	AIII 470	001470	AIII 570	AIII 4 /0	001470	AIII 570	AIII 4 /0	ODI 470
None/minimal sleep apnea (<5 events/hr)	66 (21.0)	153 (48.6)	135 (42.9)	26 (17.6)	74 (50.0)	69 (46.6)	40 (24.0)	79 (47.3)	66 (39.5)
Mild (5 to <15 events/hr)	82 (26.0)	97 (30.8)	104 (33.0)	37 (25.0)	37 (25.0)	36 (24.3)	45 (26.9)	60 (35.9)	68 (40.7)
Moderate (15 to <30 events/hr)	84 (26.7)	38 (12.1)	42 (13.3)	40 (27.0)	21 (14.2)	23 (15.5)	44 (26.3)	17 (10.2)	19 (11.4)
Severe (≥ 30)	83 (26.3)	27 (8.6)	34 (10.8)	45 (30.4)	16 (10.8)	20 (13.5)	38 (22.8)	11 (6.6)	14 (8.4)
Clinical categories	05 (20.5)	27 (0.0)	51(10.0)	15 (50.1)	10 (10.0)	20 (15.5)	50 (22.0)	11 (0.0)	11(0.1)
Potentially actionable (≥ 5 events/hr)	249 (79.0)	162 (51.5)	180 (57.1)	122 (82.4)	74 (50.0)	79 (53.3)	127 (76.0)	88 (52.7)	101 (60.5)
<i>Clinically actionable</i> (≥ 15 events/hr)	167 (53.0)	65 (20.7)	76 (24.1)	85 (57.4)	37 (25.0)	43 (29.0)	82 (49.1)	28 (16.8)	33 (19.8)
	107 (00.0)		/0 (2)	, , , , , , , , , , , , , , , , , , ,	<u> </u>	<u> </u>		, i i i i i i i i i i i i i i i i i i i	
	· · · · · ·	All (n=303)	/	``.	Male (n=138)	X /		Female (n=16	5)
REM All categories	AHI 3%		ODI 4%	, , , , , , , , , , , , , , , , , , ,	<u> </u>	<u> </u>		, i i i i i i i i i i i i i i i i i i i	
REM	· · · · · ·	All (n=303)	/	``.	Male (n=138)	X /		Female (n=16	5)
REM All categories	AHI 3%	All (n=303) AHI 4%	/	AHI 3%	Male (n=138) AHI 4%	X /	AHI 3%	Female (n=16 AHI 4%	5)
REM All categories None/minimal sleep apnea (<5 events/hr)	AHI 3% 20 (6.6)	All (n=303) AHI 4% 58 (19.1)	/	AHI 3% 8 (5.8)	Male (n=138) AHI 4% 28 (20.3)	X /	AHI 3% 12 (7.3)	Female (n=16 AHI 4% 30 (18.2)	5)
REM All categories None/minimal sleep apnea (<5 events/hr)	AHI 3% 20 (6.6) 62 (20.5)	All (n=303) AHI 4% 58 (19.1) 75 (24.8)	/	AHI 3% 8 (5.8) 29 (21.0)	Male (n=138) AHI 4% 28 (20.3) 31 (22.5)	X /	AHI 3% 12 (7.3) 33 (20.0)	Female (n=16 AHI 4% 30 (18.2) 44 (26.7)	5)
REM All categories None/minimal sleep apnea (<5 events/hr)	AHI 3% 20 (6.6) 62 (20.5) 87 (28.7)	All (n=303) AHI 4% 58 (19.1) 75 (24.8) 76 (25.1)	/	AHI 3% 8 (5.8) 29 (21.0) 41 (29.7)	Male (n=138) AHI 4% 28 (20.3) 31 (22.5) 34 (24.6)	X /	AHI 3% 12 (7.3) 33 (20.0) 46 (27.9)	Female (n=16 AHI 4% 30 (18.2) 44 (26.7) 42 (25.5)	5)
REM All categoriesNone/minimal sleep apnea (<5 events/hr)	AHI 3% 20 (6.6) 62 (20.5) 87 (28.7)	All (n=303) AHI 4% 58 (19.1) 75 (24.8) 76 (25.1)	/	AHI 3% 8 (5.8) 29 (21.0) 41 (29.7)	Male (n=138) AHI 4% 28 (20.3) 31 (22.5) 34 (24.6)	X /	AHI 3% 12 (7.3) 33 (20.0) 46 (27.9)	Female (n=16 AHI 4% 30 (18.2) 44 (26.7) 42 (25.5)	5)
REM All categoriesNone/minimal sleep apnea (<5 events/hr)Mild (5 to <15 events/hr)Moderate (15 to <30 events/hr)Severe (\geq 30)Clinical categories	AHI 3% 20 (6.6) 62 (20.5) 87 (28.7) 134 (44.2)	All (n=303) AHI 4% 58 (19.1) 75 (24.8) 76 (25.1) 94 (31.0)	/	AHI 3% 8 (5.8) 29 (21.0) 41 (29.7) 60 (43.5)	Male (n=138) AHI 4% 28 (20.3) 31 (22.5) 34 (24.6) 45 (32.6)	X /	AHI 3% 12 (7.3) 33 (20.0) 46 (27.9) 74 (44.8)	Female (n=16 AHI 4% 30 (18.2) 44 (26.7) 42 (25.5) 49 (29.7)	5)
REM All categoriesNone/minimal sleep apnea (<5 events/hr)Mild (5 to <15 events/hr)Moderate (15 to<30 events/hr)Severe (\geq 30)Clinical categoriesPotentially actionable (\geq 5 events/hr)	AHI 3% 20 (6.6) 62 (20.5) 87 (28.7) 134 (44.2) 283 (93.4)	All (n=303) AHI 4% 58 (19.1) 75 (24.8) 76 (25.1) 94 (31.0) 245 (80.9) 170 (56.1)	/	AHI 3% 8 (5.8) 29 (21.0) 41 (29.7) 60 (43.5) 130 (94.2) 101 (73.2)	Male (n=138) AHI 4% 28 (20.3) 31 (22.5) 34 (24.6) 45 (32.6) 110 (79.7)	ODI 4%	AHI 3% 12 (7.3) 33 (20.0) 46 (27.9) 74 (44.8) 153 (92.7) 120 (72.7)	Female (n=16 AHI 4% 30 (18.2) 44 (26.7) 42 (25.5) 49 (29.7) 135 (81.9) 91 (55.2)	5) ODI 4%
REM All categoriesNone/minimal sleep apnea (<5 events/hr)	AHI 3% 20 (6.6) 62 (20.5) 87 (28.7) 134 (44.2) 283 (93.4)	All (n=303) AHI 4% 58 (19.1) 75 (24.8) 76 (25.1) 94 (31.0) 245 (80.9)	/	AHI 3% 8 (5.8) 29 (21.0) 41 (29.7) 60 (43.5) 130 (94.2) 101 (73.2)	Male (n=138) AHI 4% 28 (20.3) 31 (22.5) 34 (24.6) 45 (32.6) 110 (79.7) 79 (57.2)	ODI 4%	AHI 3% 12 (7.3) 33 (20.0) 46 (27.9) 74 (44.8) 153 (92.7) 120 (72.7)	Female (n=16 AHI 4% 30 (18.2) 44 (26.7) 42 (25.5) 49 (29.7) 135 (81.9)	5) ODI 4%
REM All categoriesNone/minimal sleep apnea (<5 events/hr)	AHI 3% 20 (6.6) 62 (20.5) 87 (28.7) 134 (44.2) 283 (93.4) 221 (72.9)	All (n=303) AHI 4% 58 (19.1) 75 (24.8) 76 (25.1) 94 (31.0) 245 (80.9) 170 (56.1) All (n=303)	ODI 4%	AHI 3% 8 (5.8) 29 (21.0) 41 (29.7) 60 (43.5) 130 (94.2) 101 (73.2)	Male (n=138) AHI 4% 28 (20.3) 31 (22.5) 34 (24.6) 45 (32.6) 110 (79.7) 79 (57.2) Male (n=138)	ODI 4%	AHI 3% 12 (7.3) 33 (20.0) 46 (27.9) 74 (44.8) 153 (92.7) 120 (72.7)	Female (n=16 AHI 4% 30 (18.2) 44 (26.7) 42 (25.5) 49 (29.7) 135 (81.9) 91 (55.2) Female (n=16	5) ODI 4%
REM All categoriesNone/minimal sleep apnea (<5 events/hr)	AHI 3% 20 (6.6) 62 (20.5) 87 (28.7) 134 (44.2) 283 (93.4) 221 (72.9)	All (n=303) AHI 4% 58 (19.1) 75 (24.8) 76 (25.1) 94 (31.0) 245 (80.9) 170 (56.1) All (n=303)	ODI 4%	AHI 3% 8 (5.8) 29 (21.0) 41 (29.7) 60 (43.5) 130 (94.2) 101 (73.2)	Male (n=138) AHI 4% 28 (20.3) 31 (22.5) 34 (24.6) 45 (32.6) 110 (79.7) 79 (57.2) Male (n=138)	ODI 4%	AHI 3% 12 (7.3) 33 (20.0) 46 (27.9) 74 (44.8) 153 (92.7) 120 (72.7)	Female (n=16 AHI 4% 30 (18.2) 44 (26.7) 42 (25.5) 49 (29.7) 135 (81.9) 91 (55.2) Female (n=16	5) ODI 4%
REM All categoriesNone/minimal sleep apnea (<5 events/hr)	AHI 3% 20 (6.6) 62 (20.5) 87 (28.7) 134 (44.2) 283 (93.4) 221 (72.9) AHI 3% 68 (22.4) 113 (37.3)	All (n=303) AHI 4% 58 (19.1) 75 (24.8) 76 (25.1) 94 (31.0) 245 (80.9) 170 (56.1) All (n=303) AHI 4% 133 (43.9) 99 (32.7)	ODI 4%	AHI 3% 8 (5.8) 29 (21.0) 41 (29.7) 60 (43.5) 130 (94.2) 101 (73.2) AHI 3% 25 (18.1) 44 (31.9)	Male (n=138) AHI 4% 28 (20.3) 31 (22.5) 34 (24.6) 45 (32.6) 110 (79.7) 79 (57.2) Male (n=138) AHI 4% 50 (36.2) 42 (30.4)	ODI 4%	AHI 3% 12 (7.3) 33 (20.0) 46 (27.9) 74 (44.8) 153 (92.7) 120 (72.7) AHI 3% 43 (26.1) 69 (41.8)	Female (n=16 AHI 4% 30 (18.2) 44 (26.7) 42 (25.5) 49 (29.7) 135 (81.9) 91 (55.2) Female (n=16 AHI 4% 83 (50.3) 57 (34.5)	5) ODI 4%
REM All categoriesNone/minimal sleep apnea (<5 events/hr)	AHI 3% 20 (6.6) 62 (20.5) 87 (28.7) 134 (44.2) 283 (93.4) 221 (72.9) AHI 3% 68 (22.4) 113 (37.3) 78 (25.7)	All (n=303) AHI 4% 58 (19.1) 75 (24.8) 76 (25.1) 94 (31.0) 245 (80.9) 170 (56.1) All (n=303) AHI 4% 133 (43.9) 99 (32.7) 50 (16.5)	ODI 4%	AHI 3% 8 (5.8) 29 (21.0) 41 (29.7) 60 (43.5) 130 (94.2) 101 (73.2) AHI 3% 25 (18.1) 44 (31.9) 42 (30.4)	Male (n=138) AHI 4% 28 (20.3) 31 (22.5) 34 (24.6) 45 (32.6) 110 (79.7) 79 (57.2) Male (n=138) AHI 4% 50 (36.2) 42 (30.4) 33 (23.9)	ODI 4%	AHI 3% 12 (7.3) 33 (20.0) 46 (27.9) 74 (44.8) 153 (92.7) 120 (72.7) AHI 3% 43 (26.1) 69 (41.8) 36 (21.8)	Female (n=16 AHI 4% 30 (18.2) 44 (26.7) 42 (25.5) 49 (29.7) 135 (81.9) 91 (55.2) Female (n=16 AHI 4% 83 (50.3) 57 (34.5) 17 (10.3)	5) ODI 4%
REM All categoriesNone/minimal sleep apnea (<5 events/hr)	AHI 3% 20 (6.6) 62 (20.5) 87 (28.7) 134 (44.2) 283 (93.4) 221 (72.9) AHI 3% 68 (22.4) 113 (37.3)	All (n=303) AHI 4% 58 (19.1) 75 (24.8) 76 (25.1) 94 (31.0) 245 (80.9) 170 (56.1) All (n=303) AHI 4% 133 (43.9) 99 (32.7)	ODI 4%	AHI 3% 8 (5.8) 29 (21.0) 41 (29.7) 60 (43.5) 130 (94.2) 101 (73.2) AHI 3% 25 (18.1) 44 (31.9)	Male (n=138) AHI 4% 28 (20.3) 31 (22.5) 34 (24.6) 45 (32.6) 110 (79.7) 79 (57.2) Male (n=138) AHI 4% 50 (36.2) 42 (30.4)	ODI 4%	AHI 3% 12 (7.3) 33 (20.0) 46 (27.9) 74 (44.8) 153 (92.7) 120 (72.7) AHI 3% 43 (26.1) 69 (41.8)	Female (n=16 AHI 4% 30 (18.2) 44 (26.7) 42 (25.5) 49 (29.7) 135 (81.9) 91 (55.2) Female (n=16 AHI 4% 83 (50.3) 57 (34.5)	5) ODI 4%
REMAll categoriesNone/minimal sleep apnea (<5 events/hr)	AHI 3% 20 (6.6) 62 (20.5) 87 (28.7) 134 (44.2) 283 (93.4) 221 (72.9) AHI 3% 68 (22.4) 113 (37.3) 78 (25.7) 44 (14.5)	All (n=303) AHI 4% 58 (19.1) 75 (24.8) 76 (25.1) 94 (31.0) 245 (80.9) 170 (56.1) All (n=303) AHI 4% 133 (43.9) 99 (32.7) 50 (16.5) 21 (6.9)	ODI 4%	AHI 3% 8 (5.8) 29 (21.0) 41 (29.7) 60 (43.5) 130 (94.2) 101 (73.2) AHI 3% 25 (18.1) 44 (31.9) 42 (30.4)	Male (n=138) AHI 4% 28 (20.3) 31 (22.5) 34 (24.6) 45 (32.6) 110 (79.7) 79 (57.2) Male (n=138) AHI 4% 50 (36.2) 42 (30.4) 33 (23.9) 13 (9.4)	ODI 4%	AHI 3% 12 (7.3) 33 (20.0) 46 (27.9) 74 (44.8) 153 (92.7) 120 (72.7) AHI 3% 43 (26.1) 69 (41.8) 36 (21.8)	Female (n=16 AHI 4% 30 (18.2) 44 (26.7) 42 (25.5) 49 (29.7) 135 (81.9) 91 (55.2) Female (n=16 AHI 4% 83 (50.3) 57 (34.5) 17 (10.3) 8 (4.8)	5) ODI 4%
REMAll categoriesNone/minimal sleep apnea (<5 events/hr)	AHI 3% 20 (6.6) 62 (20.5) 87 (28.7) 134 (44.2) 283 (93.4) 221 (72.9) AHI 3% 68 (22.4) 113 (37.3) 78 (25.7)	All (n=303) AHI 4% 58 (19.1) 75 (24.8) 76 (25.1) 94 (31.0) 245 (80.9) 170 (56.1) All (n=303) AHI 4% 133 (43.9) 99 (32.7) 50 (16.5)	ODI 4%	AHI 3% 8 (5.8) 29 (21.0) 41 (29.7) 60 (43.5) 130 (94.2) 101 (73.2) AHI 3% 25 (18.1) 44 (31.9) 42 (30.4)	Male (n=138) AHI 4% 28 (20.3) 31 (22.5) 34 (24.6) 45 (32.6) 110 (79.7) 79 (57.2) Male (n=138) AHI 4% 50 (36.2) 42 (30.4) 33 (23.9)	ODI 4%	AHI 3% 12 (7.3) 33 (20.0) 46 (27.9) 74 (44.8) 153 (92.7) 120 (72.7) AHI 3% 43 (26.1) 69 (41.8) 36 (21.8)	Female (n=16 AHI 4% 30 (18.2) 44 (26.7) 42 (25.5) 49 (29.7) 135 (81.9) 91 (55.2) Female (n=16 AHI 4% 83 (50.3) 57 (34.5) 17 (10.3)	5) ODI 4%

Table S2. Sleep apnea categories by AHI 3%, AHI 4%, and ODI 4% across supine/non-supine positions and REM and non-REM sleep cycles, n (%).

AHI, apnea hypopnea index; ODI, oxygen desaturation index; REM, rapid eye movement.

Table S3. Comparison of observed sample sleep apnea category frequencies and CREBRF-adjusted prevalence estimates.

Categorical AHI 3% (events/hr)	Observed categorical	CREBRF-adjusted categorical			
Categorical ATT 5 /6 (events/iii)	counts, n (%)	counts, n (%) ¹			
All categories					
None/minimal sleep apnea (<5 events/hr)	40 (12.1)	40.3 (12.2)			
Mild (5 to <15 events/hr)	109 (33.0)	112 (33.9)			
Moderate (15 to<30 events/hr)	114 (34.6)	116 (35.2)			
Severe (≥ 30)	67 (20.3)	61.7 (18.7)			
Clinical categories					
Potentially actionable (≥ 5 events/hr)	290 (87.9)	289.7 (87.8)			
Clinically actionable (≥ 15 events/hr)	181 (54.9)	177.7 (53.9)			
Catagorical AUI 19/ (avants/hr)	Observed categorical	CREBRF-adjusted categorical			
Categorical AHI 4% (events/hr)	counts, n $(\%)$	counts, n (%) ¹			
All categories					
None/minimal sleep apnea (<5 events/hr)	104 (31.5)	108 (32.7)			
Mild (5 to <15 events/hr)	122 (37.0)	123 (37.3)			
Moderate (15 to<30 events/hr)	69 (20.9)	68.8 (20.8)			
Severe (≥ 30)	35 (10.6)	30.2 (9.2)			
Clinical categories					
Potentially actionable (≥ 5 events/hr)	226 (68.5)	222 (67.3)			
Clinically actionable (≥ 15 events/hr)	104 (31.5)	99 (30.0)			
Catagorical ODI 40/ (amonta/har)	Observed categorical	CREBRF-adjusted categorical			
Categorical ODI 4% (events/hr)	counts, n (%)	counts, n (%) ¹			
All categories					
None/minimal sleep apnea (<5 events/hr)	95 (28.8)	97.8 (29.6)			
Mild (5 to <15 events/hr)	121 (36.7)	123.1 (37.3)			
Moderate (15 to<30 events/hr)	74 (22.4)	73.6 (22.3)			
Severe (≥ 30)	40 (12.1)	35.5 (10.8)			
Clinical categories					
Potentially actionable (\geq 5 events/hr)	235 (71.2)	232.2 (70.4)			
Clinically actionable (≥ 15 events/hr)	114 (34.5)	109.1 (33.1)			


n=330. ¹To estimate sleep apnea category prevalence that adjusts for sample ascertainment bias (i.e., *CREBRF* obesity-risk allele oversampling) and is therefore likely more generalizable to the population, we used post-stratification calibration as shown in Code S1. This approach was similar to inverse probability weighting in that each individual observation was weighted by their chance of being in the sample. Specifically, we estimated genotype-specific weights as the observed/expected genotype frequency and then sleep apnea category counts were adjusted based on genotype. Observed sample genotype frequencies of GG=0.439, AG=0.421, and AA=0.139; expected genotype frequencies (based on population minor allele frequency of 0.259) of GG=0.549, AG=0.383, and AA=0.067; genotype specific weights of GG=1.251, AG=0.910, AA=0.482.

Table S4. Categorical percent time spent <90% oxygen saturation, broken down by sleep apnea category.

All participants (n=330		Sleep apnea category							
Hypoxia category ¹		None (n=40)	Mild (n=109)	Moderate (n=114)	Severe (n=67)				
0%	0% None		46 (42.2)	9 (7.9)	0				
>0 to <5%	Light	9 (22.5)	63 (57.8)	95 (83.3)	34 (50.7)				
5% to <10%	Mild	0	0	8 (7.0)	8 (11.9)				
10% to <25%	Moderate	0	0	2 (1.8)	19 (28.4)				
≥25%	≥25% Severe		0	0	6 (9.0)				
Male participants (n=1	54)		Sleep	apnea category					
Hypoxia ca	ategory ¹	None (n=18)	Mild (n=41)	Moderate (n=54)	Severe (n=41)				
0%	None	12 (66.7)	17 (41.5)	7 (13.0)	0				
>0 to <5%	Light	6 (33.3)	24 (58.5)	44 (81.5)	16 (39.0)				
5% to <10%	Mild	0	0	3 (5.6)	4 (9.8)				
10% to <25%	Moderate	0	0	0	18 (43.9)				
≥25%	≥25% Severe		0	0	3 (7.3)				
Female participants (n	Female participants (n=176)		Sleep	apnea category					
Hypoxia category ¹		None (n=22)	Mild (n=68)	Moderate (n=60)	Severe (n=26)				
0%	None	19 (86.4)	29 (42.6)	2 (3.3)	0				
>0 to <5%	Light	3 (13.6)	39 (57.4)	51 (85.0)	18 (69.2)				
5% to <10%	Mild	0	0	5 (8.3)	4 (15.4)				
10% to <25%	Moderate	0	0	2 (3.3)	1 (3.8)				
≥25%	Severe	0	0	0	3 (11.5)				

¹Based on % time spent at <90% oxygen saturation


Figure S1. Sina with violin plots of sleep apnea measures by categorical participant characteristics.



AHI = apnea hypopnea index; ODI = oxygen desaturation index; Age (years); BMI (kg/m²), 'Normal' = 18-25.99 kg/m², Overweight = 26-32 kg/m², Obesity = >32 kg/m²; Hypertension, defined as an average value \geq 140/90 mmHg and/or current hypertension medication use; Diabetes, Type 2 diabetes status was determined based on any of the following: current use of diabetes medication,

Hemoglobin A1c (HbA1c) (5.7-6.4%, pre-diabetes; >6.4%, diabetes), fasting blood glucose (FBG; 100-125, pre-diabetes; >126, diabetes), and/or oral glucose tolerance testing based on the American Diabetes Association criteria; Asthma, self-report history of asthma diagnosis; Smoking, defined based on self-report of current use of cigarettes, cigars, or pipes; Alcohol, defined based on self-report of consumption of alcohol in the past 12 months; Not partnered = never married, separated, divorced, or widowed; Partnered = currently married or cohabitating; *CREBRF* genotype corresponds to rs373863828, minor allele = A; AUA = Apia Urban Area; NWU = Northwest 'Upolu; ROU = Rest of 'Upolu. Black horizontal line depicts subgroup median; green horizontal line indicates p-value < 0.05. Wilcox test used for binary variables, Kruskal-Wallis test used for variables with more than two levels.

Figure S2. Sina with violin plots of sleep apnea measures by additional sleep environmental factors.



AHI = apnea hypopnea index; ODI = oxygen desaturation index; Room sharing = number of people sharing a room the night of the WatchPAT assessment, >3 category ranges from 3-9; Bed sharing = number of people sharing the sleep surface the night of the WatchPAT assessment, >3 category ranges from 3-9; Sleep surface = sleep surface the night of the WatchPAT assessment, other category includes carpet/floor/blanket/mat on sofa/sofa. Black horizontal line depicts subgroup median. Wilcox test used for binary variables, Kruskal-Wallis test used for variables with more than two levels.





Figure S3. Rain cloud plots describing sleep apnea measures more detailed age group and sex.

AHI = apnea hypopnea index; ODI = oxygen desaturation index. Black horizontal line depicts subgroup median.

Figure S4. Scatterplots of sleep apnea measures by continuous level participant characteristics.



AHI = apnea hypopnea index; ODI = oxygen desaturation index; Age (years); BMI (kg/m²); Physical activity, moderate-vigorous physical activity (min/day) measured using accelerometer; Household assets as a measure of material lifestyle score/socioeconomic position. R, Spearman correlation coefficient; p-value evaluated a null hypothesis of R=0; blue line indicates fitted linear regression line; gray shading indicates 95% confidence interval for regression line.

Table S5. Results of linear regression examining associations of square root transformed sleep apnea measures with *CRBERF* genotype while controlling for age and sex (Table S3a), *CREBRF* genotype while controlling for age, sex, and BMI (Table S3b), and *CREBRF* genotype while controlling for age, sex, and T2DM (Table S3c).

Table S3a. No covariates (n=330)												
AHI 3%			AHI 4%				ODI 4%					
Term	$\widehat{oldsymbol{eta}}$	2.5th	97.5th	р	β	2.5th	97.5th	р	β	2.5th	97.5th	р
CREBRF genotype	0.364	0.116	0.611	0.004	0.394	0.137	0.652	0.003	0.396	0.137	0.656	0.003
Age	0.024	0.007	0.042	0.007	0.022	0.004	0.040	0.020	0.022	0.003	0.040	0.022
Sex, Female (Ref=Male)	-0.458	-0.806	-0.110	0.013	-0.497	-0.858	-0.135	0.008	-0.543	-0.908	-0.178	0.004
Table S3b. Controlling for BMI (n	i=329)											
	AHI 3%					A	AHI 4%		ODI 4%			
Term	$\widehat{oldsymbol{eta}}$	2.5th	97.5th	р	β	2.5th	97.5th	р	β	2.5th	97.5th	р
CREBRF genotype	0.085	-0.127	0.296	0.433	0.094	-0.122	0.310	0.394	0.096	-0.123	0.314	0.391
BMI	0.127	0.106	0.148	2.03E-27	0.138	0.116	0.159	<u>3.44E-30</u>	0.138	0.116	0.159	1.09E-29
Age	0.036	0.021	0.050	3.49E-06	0.034	0.019	0.049	1.38E-05	0.034	0.018	0.049	1.97E-05
Sex	-0.966	-1.269	-0.664	1.27E-09	-1.052	-1.361	-0.743	1.12E-10	-1.099	-1.412	-0.786	3.05E-11
Table S3c. Controlling for T2DM	(n=328)											
AHI 3%					AHI 4%			ODI 4%				
Term	$\widehat{oldsymbol{eta}}$	2.5th	97.5th	р	β	2.5th	97.5th	р	β	2.5th	97.5th	р
CREBRF genotype	0.397	0.144	0.650	0.002	0.435	0.172	0.698	0.028	0.437	0.172	0.702	0.001
Pre-T2DM (Ref=No diabetes)	0.411	-0.148	0.969	0.151	0.418	-0.163	0.998	0.159	0.418	-0.168	1.003	0.163
T2DM (Ref=No diabetes)	0.399	-0.201	0.999	0.193	0.456	-0.167	1.079	0.152	0.457	-0.171	1.086	0.155
Age	0.023	0.004	0.411	0.016	0.020	0.001	0.039	0.045	0.019	8.45E-05	0.386	0.049
Sex	-0.475	-0.826	-0.124	0.008	-0.522	-0.886	-0.157	0.005	-0.567	-0.935	-0.200	0.003


 $\hat{\beta}$ = regression estimate for square root transformed dependent variable (sleep apnea measure).

2.5th = lower bound of 95% confidence interval for $\hat{\beta}$; 97.5th = upper bound of 95% confidence interval for $\hat{\beta}$.

Underlined p-values indicate p<0.05.


CREBRF rs373863828 genotype modeled additively based on number of copies of minor allele; BMI = body mass index (kg/m2); Pre-T2DM = pre-type 2 diabetes; T2DM = type 2 diabetes.

Figure S5. Mosaic plot depicting the proportional distribution of sleep apnea categories by categorical BMI and sex.




Category = AHI 3% categorized based on the number of events/hr: None (<5), Mild (5-14.9), Moderate (15-29.9), Severe (\geq 30). BMI, body mass index categorized: Normal (18.5 to <26 kg/m²), Overweight (26 to 32 kg/m²), Obesity (\geq 32 kg/m²). Sex: M = male, F = female. Plot interpretation: The size of the tile is proportional to the percentage of cases in that combination of levels; assuming the three variables of interest are independent, blue shading indicates more cases than expected while red shading indicates less cases than expected (e.g., within the severe category, we see a greater number of males than expected while in the none and mild categories, we see a lower number of males than expected, suggesting a compounding of effect of sex on categorical BMI).

Figure S6. Mosaic plot depicting the proportional distribution of sleep apnea categories by categorical BMI and categorical age.




Category = AHI 3% categorized based on the number of events/hr: None (<5), Mild (5-14.9), Moderate (15-29.9), Severe (\geq 30). BMI, body mass index categorized: Normal (18.5 to <26 kg/m²), Overweight (26 to 32 kg/m²), Obesity (\geq 32 kg/m²). Age: A \geq 50 years, B < 50 years. Plot interpretation: The size of the tile is proportional to the percentage of cases in that combination of levels; assuming the three variables of interest are independent, blue shading indicates more cases than expected while red shading indicates less cases than expected.

Figure S7. Mosaic plot depicting the proportional distribution of sleep apnea categories by categorical age and sex.



Category = AHI 3% categorized based on the number of events/hr: None (<5), Mild (5-14.9), Moderate (15-29.9), Severe (\geq 30). Age: A \geq 50 years, B < 50 years. Sex: M = male, F = female. Plot interpretation: The size of the tile is proportional to the percentage of cases in that combination of levels; assuming the three variables of interest are independent, blue shading indicates more cases than expected while red shading indicates less cases than expected.

Figure S8. Mosaic plot depicting the proportional distribution of sleep apnea categories by *CREBRF* rs373863828 genotype and sex.



Category = AHI 3% categorized based on the number of events/hr: None (<5), Mild (5-14.9), Moderate (15-29.9), Severe (\geq 30). Sex: M = male, F = female. Plot interpretation: The size of the tile is proportional to the percentage of cases in that combination of levels; assuming the three variables of interest are independent, blue shading indicates more cases than expected while red shading indicates less cases than expected.

SAMOA WATCHPAT REFERENCES

1. Zhang Z, Sowho M, Otvos T, et al. A comparison of automated and manual sleep staging and respiratory event recognition in a portable sleep diagnostic device with in-lab sleep study. *J Clin Sleep Med.* 2020;16(4):563-573. doi:10.5664/jcsm.8278